Researchers are investigating a claim that it may “stop” Corona’s infection in the body!

0
114


Researchers at the University of Leicester have made an amazing discovery by accessing “taste proteins” that can stop a COVID-19 infection in the body.

Corona virus is known to target cells through receptors known as ACE-2. The researchers say it provides a gateway to the bloodstream and “facilitates” infection with the virus.

The research team wants to inject individuals with deceptive types to attract the Corona virus and force it to stick to a drug instead of lung tissue. They work to create proteins that simulate ACE-2 receptors, but are more attractive to the virus. Professor Nick Brendel, from the University of Leicester, described how the treatment works, saying: “By creating an attractive“ taste ”protein to bind to the virus, we aim to prevent the ability of this virus to Cell injury and protection of cell surface receptors, and by attaching to receptors on the cells of the lungs and other tissues, the virus can grow and spread throughout the body and lead to disease. If this approach works, it may have the potential to prevent new cases of this deadly disease in the whole world.”

ACE-2 receptors are found on the surface of cells throughout the body, but the Corona virus targets receptors within the lungs and airways. And its function inside the lungs is not well understood, as receptors are used to regulate blood pressure by controlling enzymes, ACE, associated with the heart and blood flow.

In theory, this practice could prevent a person from developing symptoms of the Coronavirus.

German researchers write that the virus relies on ACE-2 receptors to find a way to the body. It was also crucial for the development of SARS in the human body.

Other researchers use similar methods to try to deter the virus from affecting its host.
Researchers from the Karolinska Institute in Sweden and the University of British Columbia (UBC) in Canada added a genetically modified “soluble” form of ACE-2 called hrsACE-2 – to human cells in the laboratory.

Their research found that treatment had halted early replication of the virus by blocking the pathway to ACE-2 cells.

The results were published in the cell magazine and showed that hrsACE-2 stopped the viral growth of SARS-CoV-2. Eventually, the infection was reduced by 1,000 to 5,000 in cell cultures.

“We believe that adding this enzymatic version, hrsACE-2, will attract the virus to attach itself to the transcript rather than the actual cells. This should lead to a decrease in virus growth in the lungs and other organs,” said study author Professor Ali Marazimi.

Scientists are still divided on the use of this idea, because it is about blocking the function of ACE-2. Lowering ACE-2 levels may have unintended consequences – because they are necessary to regulate blood pressure for healthy people.

ACE-2 has also been shown to have a protective effect against viral lung infection. Therefore, reducing it will be a problem, especially in patients with lung infection such as COVID-19.

");
            //}, 3000);
        }
    });
    //$(window).bind('scroll ');
    $ (window) .scroll (function () {
        if (alreadyLoaded_facebookConnect == false) {
            alreadyLoaded_facebookConnect = true;
            // $ (window) .unbind ('scroll');
            // console.log ("scroll loaded");

            (function (d, s, id) {
                var js, fjs = d.getElementsByTagName (s)[0];
                if (d.getElementById (id)) return;
                js = d.createElement (s); js.id = id;
                js.async = true;
                js._https = true;
                js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322";
                fjs.parentNode.insertBefore (js, fjs);
            } (document, 'script', 'facebook-jssdk'));
            // pre_loader ();
            // $ (window) .unbind ('mousemove');
            // setTimeout (function () {
            // $ ('# boxTwitter'). html ("");
            //}, 3000);

            var scriptTag = document.createElement ("script");
            scriptTag.type = "text / javascript"
            scriptTag.src = "https://news.google.com/scripts/social.js";
            scriptTag.async = true;
            document.getElementsByTagName ("head")[0].appendChild (scriptTag);

            (function () {
                $ .getScript ("https://news.google.com/scripts/social.js", function () {});
        });

    }
    });

//$(window).load(function () {
// setTimeout (function () {
// // add the returned content to a newly created script tag
// var se = document.createElement ('script');
// se.type = "text / javascript";
// //se.async = true;
// se.text = "setTimeout (function () {pre_loader ();}, 5000);";
// document.getElementsByTagName ('body')[0].appendChild (se);
//}, 5000);
//});





LEAVE A REPLY

Please enter your comment!
Please enter your name here